Pharmaceutical Business
Clinical Development as of July 31, 2025

＜In-house development＞

Code (Generic Name)	Potential Indication/Dosage form	Mechanism		Phase（Region）	Origin	Note
JTE-052 （delgocitinib）	Autoimmune/allergic diseases /Oral, Topical	JAK inhibitor	Suppresses overactive immune response via inhibition of Janus kinase (JAK) related to immune signal.	Phase1 (Japan)	In-house	
JTE-051	Interstitial cystitis/Bladder pain syndrome, Autoinflammatory/ Autoimmune diseases /Oral	TrkA/ITK inhibitor	Suppresses pain and overactive immune response by inhibiting TrkA and ITK.	Phase2 (Japan) Phase2 (Overseas)	In-house	
JTT-662	Type 2 diabetes mellitus /Oral	SGLT1 inhibitor	Suppresses postprandial hyperglycemia and normalizes blood glucose level via inhibition of SGLT1.	Phase1 (Overseas)	In-house	
JTT-861	Chronic heart failure /Oral	PDHK inhibitor	Improves cardiac function by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism.	Phase2 (Overseas)	In-house	
JTE-061 (tapinarof)	Atopic dermatitis (pediatric) /Topical	AhR modulator	Suppresses skin inflammation via activation of the aryl hydrocarbon receptor (AhR)	Phase3 (Japan)	In-license	・In-license from Dermavant Sciences GmbH, an Organon Company ・Co-development with Torii
JTC-064	Neurodegenerative disease /Oral	PDHK inhibitor	Improves metabolic abnormalities by activation of pyruvate dehydrogenase (PDH)	Phase1 (Overseas)	In-house	
JTV-161	Pulmonary arterial hypertension /Oral	Pim-1 inhibitor	Suppresses pulmonary vascular cell proliferation by inhibiting Pim-1	Phase1 (Overseas)	In-house	
JTE-162	Autoinflammatory/ Autoimmune diseases /Oral	NLRP3 inhibitor	Suppresses immune response by inhibition of NLRP3 inflammasome	Phase1 (Overseas)	In-house	
JTV-261	Thrombosis /Oral	PLD1/2 inhibitor	Suppresses shear-dependent platelet aggregation by inhibiting PLD1/2	Phase1 (Japan)	In-house	
JTC-262	Neurodegenerative disease /Oral	NLRP3 inhibitor	Suppresses immune response by inhibition of NLRP3 inflammasome	Phase1 (Overseas)	In-house	
JTV-263	Peripheral artery disease /Oral	H-PGDS inhibitor	Improve blood flow in ischemic lower extremities by inhibiting H-PGDS	Phase1 (Overseas)	In-house	

Clinical trial phase presented above is based on the first dose.
We are also conducting additional studies to examine the potential for use in additional dosage forms.

＜Licensed compounds＞

Compound （JT's code）	Licensee	Mechanism		Note
trametinib	Novartis	MEK inhibitor	Inhibits cellular growth by specifically inhibiting the activity of MAPK/ERK pathway.	
delgocitinib	LEO Pharma ROHTO Pharmaceutical	JAK inhibitor	Suppresses overactive immune response via inhibition of Janus kinase (JAK) related to immune signal.	
enarodustat	JW Pharmaceutical Salubris	HIF-PH inhibitor	Increases red blood cells by stimulating production of erythropoietin, an erythropoiesis-stimulating hormone, via inhibition of HIF-PH.	

Updates since the previous announcement on May 7, 2025

・JTE-051 : Potential Indication / Mechanism

・delgocitinib : JT's license partner LEO Pharma issued a statement that the U.S. Food and Drug Administration has approved delgocitinib cream 20 mg/g (2%) (Anzupgo®) for the treatment of adult patients with moderate to severe chronic hand eczema, who have had an inadequate response to, or for whom topical corticosteroids are not advisable. (July 23, 2025)